Journal of neuroimmunology · 2026
Association between irritable bowel syndrome and Guillain-Barré syndrome-related immune-mediated peripheral neuropathies: A nationwide cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bae Youngoh, Jang Miyoung, Bak Kwan-Young, Park Jin Hoon, Shin Won-Suk, Jeon Sang Ryong, Jung Hohyun
Аннотация
BACKGROUND: Irritable bowel syndrome (IBS) is recognized as a systemic disorder involving gut-brain-immune axis dysregulation, but its long-term association with immune-mediated peripheral neuropathies, including Guillain-Barré syndrome (GBS), is unclear.
METHODS: We conducted a nationwide retrospective cohort study using the Korean National Health Insurance database, including approximately 2 million adults from 2012 to 2023. Incident IBS cases were identified after a 3-year washout period and matched 1:2 with controls by age, sex, and health examination year. Primary outcomes were GBS immune-mediated peripheral neuropathies and GBS and related immune-mediated peripheral neuropathies defined by ICD-10 codes; classic GBS was a secondary outcome. Cox proportional hazards models were applied.
RESULTS: Among 141,781 patients with IBS and matched controls, IBS was associated with increased risk of the primary outcomes (incidence rate ratio, 1.57; 95% CI, 1.48-1.66). In fully adjusted models, IBS remained associated with GBS immune-mediated peripheral neuropathies (adjusted HR, 1.58; 95% CI, 1.44-1.73) and GBS and related immune-mediated peripheral neuropathies (adjusted HR, 1.50; 95% CI, 1.37-1.65), but not with classic GBS (adjusted HR, 1.25; 95% CI, 0.55-2.87).
CONCLUSIONS: IBS was associated with increased long-term risk of GBS spectrum immune-mediated peripheral neuropathies, suggesting a potential association with systemic immune-related condition.
METHODS: We conducted a nationwide retrospective cohort study using the Korean National Health Insurance database, including approximately 2 million adults from 2012 to 2023. Incident IBS cases were identified after a 3-year washout period and matched 1:2 with controls by age, sex, and health examination year. Primary outcomes were GBS immune-mediated peripheral neuropathies and GBS and related immune-mediated peripheral neuropathies defined by ICD-10 codes; classic GBS was a secondary outcome. Cox proportional hazards models were applied.
RESULTS: Among 141,781 patients with IBS and matched controls, IBS was associated with increased risk of the primary outcomes (incidence rate ratio, 1.57; 95% CI, 1.48-1.66). In fully adjusted models, IBS remained associated with GBS immune-mediated peripheral neuropathies (adjusted HR, 1.58; 95% CI, 1.44-1.73) and GBS and related immune-mediated peripheral neuropathies (adjusted HR, 1.50; 95% CI, 1.37-1.65), but not with classic GBS (adjusted HR, 1.25; 95% CI, 0.55-2.87).
CONCLUSIONS: IBS was associated with increased long-term risk of GBS spectrum immune-mediated peripheral neuropathies, suggesting a potential association with systemic immune-related condition.